# REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

> **NCT05669755** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 7101 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05669755
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-10-13
- **Target enrollment:** 7101 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669755, "REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05669755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*